Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung

The global Phase III LUX-Lung 8 trial (ClinicalTrials.gov: NCT01523587) identified significant improvements in progression-free survival (PFS), overall survival (OS), and patient-reported outcomes (PROs) with second-line afatinib vs erlotinib in patients with advanced squamous cell carcinoma (SCC) o...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	OncoTargets and therapy 2018-01, Vol.11, p.8565-8573
Hauptverfasser:	Lu, Shun, Li, Wei, Zhou, Caicun, Hu, Cheng-Ping, Qin, Shukui, Cheng, Gang, Feng, Jifeng, Wang, Jie, Cseh, Agnieszka, Peil, Barbara, Gibson, Neil, Ehrnrooth, Eva, Zhang, Li
Format:	Artikel
Sprache:	eng
Schlagworte:	Afatinib Antineoplastic agents Atezolizumab Cancer therapies Carcinoma Care and treatment Chemotherapy Clinical trials Comparative analysis Death Development and progression Diarrhea Drug dosages Erlotinib Histology Hospitals Inhibitor drugs Internal medicine Lung cancer Medicine Mutation Nivolumab Non-small cell lung cancer Oncology Operating systems (Software) Original Research Pain Patients Pembrolizumab Quality of life Questionnaires Ramucirumab Regulatory approval Retirement benefits Squamous cell carcinoma Targeted cancer therapy Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!